My final case counts in just 1 yr of fellowship @EndourologyNm under @amy_krambeck:
572 cases (PCNL, URS, HoLEP not including stents, bladder biopsies, on call cases)
226 HoLEPs
92 PCNL (including multiple bilateral PCNLs)
No better training out there. I am tired!
After receiving some questions about our recent @CCR_AACR paper that was mentioned a few times at last week’s @US_FDA workshop on NMIBC trials, it feels important to highlight our data that demonstrates exactly why randomized trials are critical to determine the true clinical benefit of any NMIBC treatments and why we urgently need to move beyond single arm trials for NMIBC drug approval 1/n
@ElaineChangMD@chana_weinstock@BladderCancerUS@UrologyMSK@bbmdmsk@bca_md@h_alahmadie
https://t.co/NMZIDN7hg2
Great effort by all. Closely proctored course consists of:
Renal vascular isolation
Partial nephrectomy
RPLND
Pelvic vascular control
IVC and aortic vascular repair
Ureteroenteric anastomosis
Ureteral repair
bowel handling/stapling
Great learning, bonding and social interaction
Uromigos Unsung Hero poster award! We discussed some pre-and post EV tissue data showing alterations in nectin-4 localization and expression. Possible implication for mechanisms of resistance! @OncoAlert
Congrats to our @SUO_YUO fellows @BeckySagerMDPhD (Modeling the effects of HIF2α inhibition on the ccRCC tumor microenvironment) and @aghasemzadeh1 (Understanding the Tumor Microenvironment in Non-muscle Invasive Bladder Cancer)
For their @ASCO YIAs!
https://t.co/KtAs3qBqXr
@eugene_pietzak incrediblely elegant P2 on bcg + Pembro in VHR T1. 92% response, 94% RC- free. 1 early death and 21% iAEs. n=37 but great job to consider risk - based strategy. #AUA26
Tomorrow at #AUA26, @eugene_pietzak will present data on combining pembrolizumab + BCG in patients with BCG-naïve very high-risk T1 non-muscle invasive #BladderCancer traditionally recommended for radical cystectomy.
10:50 a.m. ET in Hall D.
@AmerUrological@MSKCancerCenter
Session details: https://t.co/aV8knyP7e2
Highly recommend this course to trainees. Performing a quality TURBT is an undepreciated skill that has major implications for our patients. The models are exceptional! @Olympus_Corp@JoshMeeks@bbmdmsk
Here is a closer look at recent #JITC article “Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder Cancer” by @NFryden, Khyati Meghani, @bonnie_choy & @JoshMeeks, from @NM_Urology & @NU_BMG_SQE. 1/10